Market research
PDLI PDL BioPharma, Inc
NASDAQ USD Healthcare
Latest close
As of 29 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 282M
- P/E ratio
- 476.67
- Analyst target
- 2.5
- Dividend yield
- 0.0%
- Beta
- 1.14
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 282M
- P/E ratio
- 476.67
- Analyst target
- 2.5
- Dividend yield
- 0.0%
- Beta
- 1.14
About
About PDL BioPharma, Inc
PDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.
Research context
PDL BioPharma, Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the PDLI discussion.
5 years, 6 months ago
PDL BioPharma, Inc is currently in a long term downtrend where the price is trading 15.5% below its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.6.
PDL BioPharma, Inc's total revenue sank by 88.2% to $5M since the same quarter in the previous year.
Its net income has dropped by 181.0% to $-50M since the same quarter in the previous year.
Finally, its free cash flow grew by 1278.2% to $64M since the same quarter in the previous year.
Based on the above factors, PDL BioPharma, Inc gets an overall score of 2/5.